Endometrial Cancer Conservative Treatment (E.C.Co). A Multicentre Archive

Last updated: October 12, 2021
Sponsor: National Cancer Institute, Naples
Overall Status: Active - Recruiting

Phase

N/A

Condition

Endometrial Cancer

Vaginal Cancer

Pelvic Cancer

Treatment

N/A

Clinical Study ID

NCT04290299
13/15 oss
  • Ages 18-45
  • Female

Study Summary

Approximately one fourth of cases of endometrial cancer (EC) are diagnosed in premenopausal women, of whom approximately 40% wish to preserve their fertility. When arising in young women, EC usually presents with favorable prognostic features, as a focal, well differentiated endometrioid tumor, with minimal or absent myometrial invasion. This profile corresponds to the Type 1 EC, which correlates with the estrogen/progesterone receptor positive (ER+/PR+) pattern. On the other hand, these patients frequently present with clinical signs of a hyperestrogenism (chronic anovulation, infertility, obesity). Primary progestin therapy has been demonstrated to be effective in early well differentiated tumors and in poor operative candidates with response rates ranging from 58-100%.Currently, the therapeutic approach to an early stage EC consists of a staging laparotomy/laparoscopy, including a total abdominal hysterectomy and bilateral salpingo-oophorectomy (TAH-BSO), peritoneal washings, and lymphadenectomy (pelvic and aortic), depending on the pathological risk profile pre- and intraoperatively determined. Therefore, the current standard of surgical approach is preclusive of fertility.

The worldwide experience and data on conservative management of EC are, however, still limited. Most of reports based on cases retrospectively collected, harboring potential methodological bias, using different treatments and drugs, and with insufficient follow-up.

Some systematic reviews have been published in the last decade, trying to summarize the literature data. Therapeutic results seem to be promising with a regression rate of approximately 75% and relapse occurring in 25-40% of cases, with anecdotical reports of deaths of disease (DOD). The fertility outcome was, however, not satisfying with about 30% pregnancy rate in patients attempting to conceive, and an overall low rate of assisted reproductive techniques (ART) despite the subfertile clinical profile.Therefore, there is a need for a prospective, multicentre cooperative project able to systematically collect data from consecutive patients treated according to defined (not necessarily identical) protocols, concerning the oncological, as well as, the obstetrical outcomes. Moreover, this project could represent the "template" in which a pretreatment fertility counseling, psychological support, and definitive surgery are routinely included according to shared criteria.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Informed consent to personal data processing
  • Existence of an IRB-approved local protocol that allows conservative treatment to beperformed or statement that such treatment is considered as a standard (please notethat such protocols should be shared with the database owner National Cancer Instituteof Naples).

Exclusion

Exclusion Criteria:

Study Design

Total Participants: 100
Study Start date:
September 15, 2015
Estimated Completion Date:
April 08, 2025

Study Description

PURPOSE The goal of this research project is to learn more about the safety of conservatively treating EC and about subsequent fertility outcome.

PROJECT TYPE Observational (patient archive) - The project runs within the framework of Gynecologic Cancer InterGroup (GCIG), thus, participating Centres must belong to one of the qualified National groups.

PROJECT DESIGN Observational model: Cohort

TIME PERSPECTIVE Prospective

ENDPOINT CLASSIFICATION Cancer (response, relapse) and fertility (pregnancy, delivery) outcomes

INTERVENTIONS Data collection

OUTCOME MEASURES Primary outcome measures

  • Proportion of complete regression

  • Duration of response

  • Frequency and pattern of relapse

  • Frequency of metachronous ovarian cancer

  • Tumor-related deaths

Secondary outcome measures

  • Treatment related morbidity

  • Frequency of spontaneous pregnancies

  • Frequency of pregnancies after ART

  • Pattern of residual disease on definitive surgical specimens

REQUIREMENTS FOR PATIENT REGISTRATION

  • Informed consent to personal data processing

  • Existence of an IRB-approved local protocol that allows conservative treatment to be performed or statement that such treatment is considered as a standard (please note that such protocols should be shared with the database owner National Cancer Institute of Naples).

TREATMENT Since this is a archive, treatment is not dictated by a protocol. However, treatment has to be administered according to a IRB-approved local protocol (except for the countries where conservative treatment can be given outside a IRB-approved study because considered as a standard procedure).

DURATION A first phase of three years is planned, eventually followed by further three years.

PUBLICATION POLICY Data generated are property of all investigators and will be object of publication after general agreement.

DATA TO BE COLLECTED

Patient enrollment and registration of data are made by appropriate eCRFs via the Clinical Trials Unit of National Cancer Institute of Naples (Study Data Center) website through the following steps:

  1. go to http://www.usc-intnapoli.net;

  2. select language;

  3. click "Ask for authorization" to create your personal account;

  4. fill and send the "authorization form";

  5. make a screenshot of the "authorization form" and send it to l.sparavigna@istitutotumori.na.it;

  6. enter into to the system using your credentials and click on "E.C.Co.";

  7. click "the join request form";

  8. wait for authorization (a verification message will be sent to your email address within 24-48 h);

  9. enter into to the system using your credentials and click on "E.C.Co." for patient registration and/or updating.

Connect with a study center

  • ANZGOG - Australia and New Zealand Gynecological Oncology Group

    Sydney,
    Australia

    Active - Recruiting

  • AGO-AUST Arbeitsgemeinschaft Gynaekologische Onkologie

    Vienna,
    Austria

    Active - Recruiting

  • EORTC - European Organization for Research and Treatment of Cancer

    Brussels,
    Belgium

    Active - Recruiting

  • NCIC Clinical Trials Group (Canadian Cancer Society Research Institute)

    Ottawa,
    Canada

    Active - Recruiting

  • PMHC (Princess Margaret Hospital Consortium)

    Toronto,
    Canada

    Active - Recruiting

  • SGOG (Shanghai Gynecologic Oncology Group)

    Shangai,
    China

    Active - Recruiting

  • NSGO (Nordic Society of Gynecologic Oncology)

    Copenhagen,
    Denmark

    Active - Recruiting

  • GINECO - Group d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens

    Paris,
    France

    Active - Recruiting

  • AGO-De Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom

    Berlin,
    Germany

    Active - Recruiting

  • NOGGO (Nord-Ostdeutsche Gesellschaft für Gynäkologische Onkologie)

    Berlin,
    Germany

    Active - Recruiting

  • ICORG - Ireland Cooperative Oncology Research Group

    Dublin,
    Ireland

    Active - Recruiting

  • MITO (Multicenter Italian Trials in Ovarian cancer and gynecologic malignancies)

    Naples,
    Italy

    Active - Recruiting

  • GOTIC - Gynecologic Oncology Trial and Investigation Consortium

    Katō,
    Japan

    Active - Recruiting

  • JGOG - Japanese Gynecologic Oncology Group

    Tokyo,
    Japan

    Active - Recruiting

  • KGOG - Korean Gynecologic Oncology Group

    Seul,
    Korea, Republic of

    Active - Recruiting

  • DGOG - Dutch Gynecologic Oncology Group

    Amsterdam,
    Netherlands

    Active - Recruiting

  • GEICO - Grupo Espanol de Investigacion en Cancer de Ovario

    Madrid,
    Spain

    Active - Recruiting

  • SGCTG (Scottish Gynaecological Cancer Trials Group)

    Edinburgh,
    United Kingdom

    Active - Recruiting

  • Cooperative Ovarian Cancer Group (COGI)

    Stanford, California
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.